Article Versions Notes

Hubert J-N, Suybeng V, Vallée M, Delhomme TM, Maubec E, Boland A, Bacq D, Deleuze J-F, Jouenne F, Brennan P, et al. The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma. Cancers. 2021; 13(9):2243. https://doi.org/10.3390/cancers13092243

Hubert, Jean-Noël, Voreak Suybeng, Maxime Vallée, Tiffany M. Delhomme, Eve Maubec, Anne Boland, Delphine Bacq, Jean-François Deleuze, Fanélie Jouenne, Paul Brennan, and et al. 2021. "The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma" Cancers 13, no. 9: 2243. https://doi.org/10.3390/cancers13092243

Hubert, J.-N., Suybeng, V., Vallée, M., Delhomme, T. M., Maubec, E., Boland, A., Bacq, D., Deleuze, J.-F., Jouenne, F., Brennan, P., McKay, J. D., Avril, M.-F., Bressac-de Paillerets, B., & Chanudet, E. (2021). The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma. Cancers, 13(9), 2243. https://doi.org/10.3390/cancers13092243